Serial Assessment of Fertility Experiences
ConditionSickle Cell Anemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age8+
SponsorChildren's Hospital Medical Center, Cincinnati
About this trial
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
Eligibility criteria
Qualifiers
Patients with documented sickle cell anemia (SCA).
At least 8 years of age at the time of enrollment.
Enrolled on the EXTEND or SACRED study.
Provide informed consent.
Disqualifiers
Currently taking part in another treatment study (not EXTEND or SACRED).
Has received other treatments for sickle cell disease in the past 6 months.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
250 Participants
are grouped into 1 trial groupSponsors and collaborators
Children's Hospital Medical Center, Cincinnati
Lead sponsor
The University of The West Indies
Collaborator
Centro de Obstetricia y Ginecologia Recruiting Santo Domingo, Dominican Republic
Collaborator
Source ClinicalTrials.gov